Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Ardelyx Inc. (ARDX) Insider Trading Activity
Healthcare • Biotechnology • 267 employees
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Total Value
$1,796,048.96
Total Shares
1,915,814
Average Trade Value
$46,052.54
Most Active Insider
Mott David M
Total Activity: $3,429,588
Largest Single Transaction
$996,598
by Mott David M on Nov 13, 2024
30-Day Activity
2 Transactions
Volume: 20,833 shares
Value: $170,526
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
President CEO
Director, Officer
|
Apr 4, 2025 | 20,833 | $20,625 | 1,657,253 (+1.3%) | Exercise/Conversion | |
|
President CEO
Director, Officer
|
Apr 4, 2025 | 41,666 | $191,151 | 1,615,587 (-2.6%) | Sale | |
|
President CEO
Director, Officer
|
Mar 7, 2025 | 41,668 | $223,199 | 1,635,138 (-2.5%) | Sale | |
|
President CEO
Director, Officer
|
Mar 7, 2025 | 20,834 | $20,626 | 1,676,806 (+1.2%) | Exercise/Conversion | |
|
See Remarks
Officer
|
Feb 25, 2025 | 136,680 | $10,000 | 317,723 (+43.0%) | Grant | |
|
Chief Medical Officer
Officer
|
Feb 25, 2025 | 105,200 | $10,000 | 409,004 (+25.7%) | Grant | |
|
Chief Financial Officer
Officer
|
Feb 25, 2025 | 136,680 | $10,000 | 422,648 (+32.3%) | Grant | |
|
Chief Commercial Officer
Officer
|
Feb 25, 2025 | 136,680 | $10,000 | 316,680 (+43.2%) | Grant | |
|
President CEO
Director, Officer
|
Feb 25, 2025 | 570,217 | $10,000 | 1,655,972 (+34.4%) | Grant | |
|
See Remarks
Officer
|
Feb 25, 2025 | 136,680 | $10,000 | 296,680 (+46.1%) | Grant | |
|
Director
|
Feb 24, 2025 | 77,729 | $388,738 | 2,015,494 (+3.9%) | Purchase | |
|
Chief Medical Officer
Officer
|
Feb 20, 2025 | 4,941 | $27,783 | 303,804 (-1.6%) | Sale | |
|
See Remarks
Officer
|
Feb 20, 2025 | 4,291 | $24,128 | 181,043 (-2.4%) | Sale | |
|
Chief Financial Officer
Officer
|
Feb 20, 2025 | 5,171 | $29,077 | 285,968 (-1.8%) | Sale | |
|
President CEO
Director, Officer
|
Feb 20, 2025 | 22,964 | $129,124 | 1,085,755 (-2.1%) | Sale | |
|
President CEO
Director, Officer
|
Jan 31, 2025 | 20,833 | $20,625 | 1,150,385 (+1.8%) | Exercise/Conversion | |
|
President CEO
Director, Officer
|
Jan 31, 2025 | 41,666 | $223,355 | 1,108,719 (-3.8%) | Sale | |
|
Director
|
Jan 21, 2025 | 199,000 | $992,672 | 1,937,765 (+10.3%) | Purchase | |
|
Director
|
Jan 16, 2025 | 100,000 | $55,000 | 350,524 (+28.5%) | Exercise/Conversion | |
|
President CEO
Director, Officer
|
Jan 7, 2025 | 41,666 | $221,309 | 1,129,552 (-3.7%) | Sale | |
|
President CEO
Director, Officer
|
Jan 7, 2025 | 20,833 | $20,625 | 1,171,218 (+1.8%) | Exercise/Conversion | |
|
Director
|
Dec 26, 2024 | 100,000 | $55,000 | 1,738,765 (+5.8%) | Exercise/Conversion | |
|
Director
|
Dec 19, 2024 | 213,300 | $996,580 | 1,638,765 (+13.0%) | Purchase | |
|
President CEO
Director, Officer
|
Dec 10, 2024 | 25,000 | $131,620 | 1,150,385 (-2.2%) | Sale | |
|
President CEO
Director, Officer
|
Dec 10, 2024 | 25,000 | $24,750 | 1,175,385 (+2.1%) | Exercise/Conversion | |
|
President CEO
Director, Officer
|
Nov 25, 2024 | 25,000 | $134,483 | 1,150,385 (-2.2%) | Sale | |
|
Chief Development Officer
Officer
|
Nov 20, 2024 | 4,941 | $23,690 | 297,005 (-1.7%) | Sale | |
|
Chief Medical Officer
Officer
|
Nov 20, 2024 | 7,366 | $35,316 | 308,745 (-2.4%) | Sale | |
|
Chief Financial Officer
Officer
|
Nov 20, 2024 | 5,260 | $25,219 | 291,139 (-1.8%) | Sale | |
|
See Remarks
Officer
|
Nov 20, 2024 | 4,941 | $23,690 | 314,421 (-1.6%) | Sale | |
|
See Remarks
Officer
|
Nov 20, 2024 | 7,046 | $33,782 | 185,334 (-3.8%) | Sale | |
|
President CEO
Director, Officer
|
Nov 20, 2024 | 31,980 | $153,328 | 1,175,385 (-2.7%) | Sale | |
|
Chief Development Officer
Officer
|
Nov 20, 2024 | 2,243 | $10,754 | 151,373 (-1.5%) | Sale | |
|
Director
|
Nov 13, 2024 | 215,868 | $996,598 | 1,425,465 (+15.1%) | Purchase | |
|
President CEO
Director, Officer
|
Nov 11, 2024 | 2,743 | $13,441 | 1,207,365 (-0.2%) | Sale | |
|
Chief Development Officer
Officer
|
Nov 6, 2024 | 27,171 | $63,037 | 180,787 (+15.0%) | Exercise/Conversion | |
|
Chief Development Officer
Officer
|
Nov 6, 2024 | 27,171 | $165,743 | 153,616 (-17.7%) | Sale | |
|
Chief Development Officer
Officer
|
Nov 4, 2024 | 27,172 | $161,673 | 153,616 (-17.7%) | Sale | |
|
Chief Development Officer
Officer
|
Nov 4, 2024 | 27,172 | $63,039 | 180,788 (+15.0%) | Exercise/Conversion |